セリアック病治療薬の世界市場2023~2027

■ 英語タイトル:Global Celiac Diseases Drugs Market 2023-2027

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR45214-23)■ 発行会社/調査会社:Technavio
■ 商品コード:IRTNTR45214-23
■ 発行日:2023年9月21日
■ 調査対象地域:北米、ヨーロッパ、アジア、その他地域
■ 産業分野:医薬品
■ ページ数:約120
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[セリアック病治療薬の世界市場2023~2027]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

世界のセリアック病治療薬市場 2023-2027
セリアック病治療薬市場は、2022年から2027年の間に701.59百万米ドル成長すると予測されており、予測期間中にCAGRは17.01%で加速します。
セリアック病治療薬市場に関するレポートは、全体的な分析、市場規模と予測、傾向、成長ドライバー、課題、および約25のベンダーをカバーするベンダー分析を提供します。

このレポートは、現在の市場シナリオ、最新の傾向と推進力、および全体的な市場環境に関する最新の分析を提供します。 この市場は、グルテン含有食品の消費量の増加、セリアック病の蔓延、政府の取り組みによって牽引されています。

Technavio のセリアック病治療薬市場は次のように分類されます:

治療別:
- 一次治療
- 二次治療

投与経路別:
- 経口
- 非経口

地域別:
- 北米
- ヨーロッパ
- アジア
- その他の世界 (ROW)

この研究は、無機成長戦略が今後数年間のセリアック病治療薬市場の成長を促進する主な理由の1つであることを特定しています。 また、セリアック病治療における有望な開発の増加、有病率と診断の増加により、市場での大きな需要がもたらされるでしょう。

セリアック病治療薬市場に関するレポートは、次の分野をカバーしています:
- セリアック病治療薬の市場規模
- セリアック病治療薬市場予測
•セリアック病治療薬市場の産業分析

堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されており、これに沿って、このレポートには、9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbHなどの主要企業情報が含まれています。また、セリアック病治療薬市場分析レポートには、市場の成長に影響を与える今後の傾向と課題に関する情報が含まれています。 これは、企業が今後のすべての成長機会を戦略化し、活用するのに役立ちます。

本調査は、産業の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。
当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な産業インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査報告書は、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1.エグゼクティブサマリー
2.市場状況
3.市場規模
4.過去の市場規模
5.ファイブフォース分析
6.セリアック病治療薬市場のセグメンテーション:治療別
7.セリアック病治療薬市場のセグメンテーション:投与経路別
8.顧客状況
9.地理的状況
10.推進要因・課題・傾向
11.企業状況
12.企業分析
13.付録

*** レポート目次(コンテンツ)***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global celiac diseases drugs market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global celiac diseases drugs market 2017 – 2021 ($ million)
o 4.2 Therapy Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
o 4.3 Route of Administration Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Therapy
o 6.1 Market segments
o Exhibit 30: Chart on Therapy – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Therapy – Market share 2022-2027 (%)
o 6.2 Comparison by Therapy
o Exhibit 32: Chart on Comparison by Therapy
o Exhibit 33: Data Table on Comparison by Therapy
o 6.3 First line treatment – Market size and forecast 2022-2027
o Exhibit 34: Chart on First line treatment – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on First line treatment – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on First line treatment – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on First line treatment – Year-over-year growth 2022-2027 (%)
o 6.4 Second-line treatment – Market size and forecast 2022-2027
o Exhibit 38: Chart on Second-line treatment – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Second-line treatment – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Second-line treatment – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Second-line treatment – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Therapy
o Exhibit 42: Market opportunity by Therapy ($ million)
o Exhibit 43: Data Table on Market opportunity by Therapy ($ million)
• 7 Market Segmentation by Route of Administration
o 7.1 Market segments
o Exhibit 44: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Route of Administration – Market share 2022-2027 (%)
o 7.2 Comparison by Route of Administration
o Exhibit 46: Chart on Comparison by Route of Administration
o Exhibit 47: Data Table on Comparison by Route of Administration
o 7.3 Oral – Market size and forecast 2022-2027
o Exhibit 48: Chart on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Oral – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Oral – Year-over-year growth 2022-2027 (%)
o 7.4 Parenteral – Market size and forecast 2022-2027
o Exhibit 52: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Route of Administration
o Exhibit 56: Market opportunity by Route of Administration ($ million)
o Exhibit 57: Data Table on Market opportunity by Route of Administration ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 61: Chart on Geographic comparison
o Exhibit 62: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 63: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 67: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 68: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 70: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 71: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 75: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 79: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 83: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 87: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 91: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 95: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 99: Market opportunity By Geographical Landscape ($ million)
o Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 101: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 103: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 104: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 105: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 106: Matrix on vendor position and classification
o 12.3 Adaptive Biotechnologies Corp.
o Exhibit 107: Adaptive Biotechnologies Corp. – Overview
o Exhibit 108: Adaptive Biotechnologies Corp. – Product / Service
o Exhibit 109: Adaptive Biotechnologies Corp. – Key offerings
o 12.4 Almirall SA
o Exhibit 110: Almirall SA – Overview
o Exhibit 111: Almirall SA – Product / Service
o Exhibit 112: Almirall SA – Key news
o Exhibit 113: Almirall SA – Key offerings
o 12.5 Amgen Inc.
o Exhibit 114: Amgen Inc. – Overview
o Exhibit 115: Amgen Inc. – Product / Service
o Exhibit 116: Amgen Inc. – Key offerings
o 12.6 AMYRA Biotech AG
o Exhibit 117: AMYRA Biotech AG – Overview
o Exhibit 118: AMYRA Biotech AG – Product / Service
o Exhibit 119: AMYRA Biotech AG – Key offerings
o 12.7 BioLineRx Ltd.
o Exhibit 120: BioLineRx Ltd. – Overview
o Exhibit 121: BioLineRx Ltd. – Product / Service
o Exhibit 122: BioLineRx Ltd. – Key offerings
o 12.8 Bristol Myers Squibb Co.
o Exhibit 123: Bristol Myers Squibb Co. – Overview
o Exhibit 124: Bristol Myers Squibb Co. – Product / Service
o Exhibit 125: Bristol Myers Squibb Co. – Key news
o Exhibit 126: Bristol Myers Squibb Co. – Key offerings
o 12.9 Calypso Biotech BV
o Exhibit 127: Calypso Biotech BV – Overview
o Exhibit 128: Calypso Biotech BV – Product / Service
o Exhibit 129: Calypso Biotech BV – Key offerings
o 12.10 GlaxoSmithKline Plc
o Exhibit 130: GlaxoSmithKline Plc – Overview
o Exhibit 131: GlaxoSmithKline Plc – Business segments
o Exhibit 132: GlaxoSmithKline Plc – Key news
o Exhibit 133: GlaxoSmithKline Plc – Key offerings
o Exhibit 134: GlaxoSmithKline Plc – Segment focus
o 12.11 Glenmark Pharmaceuticals Ltd.
o Exhibit 135: Glenmark Pharmaceuticals Ltd. – Overview
o Exhibit 136: Glenmark Pharmaceuticals Ltd. – Product / Service
o Exhibit 137: Glenmark Pharmaceuticals Ltd. – Key offerings
o 12.12 ImmunogenX Inc.
o Exhibit 138: ImmunogenX Inc. – Overview
o Exhibit 139: ImmunogenX Inc. – Product / Service
o Exhibit 140: ImmunogenX Inc. – Key offerings
o 12.13 Johnson and Johnson
o Exhibit 141: Johnson and Johnson – Overview
o Exhibit 142: Johnson and Johnson – Business segments
o Exhibit 143: Johnson and Johnson – Key news
o Exhibit 144: Johnson and Johnson – Key offerings
o Exhibit 145: Johnson and Johnson – Segment focus
o 12.14 Precigen Inc.
o Exhibit 146: Precigen Inc. – Overview
o Exhibit 147: Precigen Inc. – Business segments
o Exhibit 148: Precigen Inc. – Key offerings
o Exhibit 149: Precigen Inc. – Segment focus
o 12.15 Sanofi
o Exhibit 150: Sanofi – Overview
o Exhibit 151: Sanofi – Business segments
o Exhibit 152: Sanofi – Key news
o Exhibit 153: Sanofi – Key offerings
o Exhibit 154: Sanofi – Segment focus
o 12.16 Takeda Pharmaceutical Co. Ltd.
o Exhibit 155: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 156: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 157: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 158: Takeda Pharmaceutical Co. Ltd. – Key offerings
o 12.17 Teva Pharmaceutical Industries Ltd.
o Exhibit 159: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 160: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 161: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 162: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 163: Teva Pharmaceutical Industries Ltd. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 164: Inclusions checklist
o Exhibit 165: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 166: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 167: Research methodology
o Exhibit 168: Validation techniques employed for market sizing
o Exhibit 169: Information sources
o 13.5 List of abbreviations
o Exhibit 170: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Therapy
Exhibits6: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global celiac diseases drugs market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Therapy – Market share 2022-2027 (%)
Exhibits31: Data Table on Therapy – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Therapy
Exhibits33: Data Table on Comparison by Therapy
Exhibits34: Chart on First line treatment – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on First line treatment – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on First line treatment – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on First line treatment – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Second-line treatment – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Second-line treatment – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Second-line treatment – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Second-line treatment – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Therapy ($ million)
Exhibits43: Data Table on Market opportunity by Therapy ($ million)
Exhibits44: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits45: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Route of Administration
Exhibits47: Data Table on Comparison by Route of Administration
Exhibits48: Chart on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Oral – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Oral – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits56: Market opportunity by Route of Administration ($ million)
Exhibits57: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits59: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits61: Chart on Geographic comparison
Exhibits62: Data Table on Geographic comparison
Exhibits63: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits67: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits99: Market opportunity By Geographical Landscape ($ million)
Exhibits100: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits101: Impact of drivers and challenges in 2022 and 2027
Exhibits102: Overview on Criticality of inputs and Factors of differentiation
Exhibits103: Overview on factors of disruption
Exhibits104: Impact of key risks on business
Exhibits105: Vendors covered
Exhibits106: Matrix on vendor position and classification
Exhibits107: Adaptive Biotechnologies Corp. – Overview
Exhibits108: Adaptive Biotechnologies Corp. – Product / Service
Exhibits109: Adaptive Biotechnologies Corp. – Key offerings
Exhibits110: Almirall SA – Overview
Exhibits111: Almirall SA – Product / Service
Exhibits112: Almirall SA – Key news
Exhibits113: Almirall SA – Key offerings
Exhibits114: Amgen Inc. – Overview
Exhibits115: Amgen Inc. – Product / Service
Exhibits116: Amgen Inc. – Key offerings
Exhibits117: AMYRA Biotech AG – Overview
Exhibits118: AMYRA Biotech AG – Product / Service
Exhibits119: AMYRA Biotech AG – Key offerings
Exhibits120: BioLineRx Ltd. – Overview
Exhibits121: BioLineRx Ltd. – Product / Service
Exhibits122: BioLineRx Ltd. – Key offerings
Exhibits123: Bristol Myers Squibb Co. – Overview
Exhibits124: Bristol Myers Squibb Co. – Product / Service
Exhibits125: Bristol Myers Squibb Co. – Key news
Exhibits126: Bristol Myers Squibb Co. – Key offerings
Exhibits127: Calypso Biotech BV – Overview
Exhibits128: Calypso Biotech BV – Product / Service
Exhibits129: Calypso Biotech BV – Key offerings
Exhibits130: GlaxoSmithKline Plc – Overview
Exhibits131: GlaxoSmithKline Plc – Business segments
Exhibits132: GlaxoSmithKline Plc – Key news
Exhibits133: GlaxoSmithKline Plc – Key offerings
Exhibits134: GlaxoSmithKline Plc – Segment focus
Exhibits135: Glenmark Pharmaceuticals Ltd. – Overview
Exhibits136: Glenmark Pharmaceuticals Ltd. – Product / Service
Exhibits137: Glenmark Pharmaceuticals Ltd. – Key offerings
Exhibits138: ImmunogenX Inc. – Overview
Exhibits139: ImmunogenX Inc. – Product / Service
Exhibits140: ImmunogenX Inc. – Key offerings
Exhibits141: Johnson and Johnson – Overview
Exhibits142: Johnson and Johnson – Business segments
Exhibits143: Johnson and Johnson – Key news
Exhibits144: Johnson and Johnson – Key offerings
Exhibits145: Johnson and Johnson – Segment focus
Exhibits146: Precigen Inc. – Overview
Exhibits147: Precigen Inc. – Business segments
Exhibits148: Precigen Inc. – Key offerings
Exhibits149: Precigen Inc. – Segment focus
Exhibits150: Sanofi – Overview
Exhibits151: Sanofi – Business segments
Exhibits152: Sanofi – Key news
Exhibits153: Sanofi – Key offerings
Exhibits154: Sanofi – Segment focus
Exhibits155: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits156: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits157: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits158: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits159: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits160: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits161: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits162: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits163: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits164: Inclusions checklist
Exhibits165: Exclusions checklist
Exhibits166: Currency conversion rates for US$
Exhibits167: Research methodology
Exhibits168: Validation techniques employed for market sizing
Exhibits169: Information sources
Exhibits170: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR45214-23 )"セリアック病治療薬の世界市場2023~2027" (英文:Global Celiac Diseases Drugs Market 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。